# The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder

> **NCT04593563** · PHASE2 · UNKNOWN · sponsor: **Maryland Oncology Hematology, PA** · enrollment: 30 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Psilocybin

## Key facts

- **NCT ID:** NCT04593563
- **Lead sponsor:** Maryland Oncology Hematology, PA
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2022-10
- **Final completion:** 2023-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04593563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04593563, "The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04593563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*